Drugs / Salmeterol/Fluticasone propionate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00158834 | Nov 1999 → ? | asthma | GlaxoSmithKline | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-08-31 | Novartis Pharmaceuticals | AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment novartis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salmeterol/Fluticasone propionate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00158834 ↗ |
| Known as | Seretide | “Salmeterol/Fluticasone Propionate Combination Product (Seretide®)” NCT00158834 ↗ |